

# REBYOTA<sup>®</sup> HAS CONFIRMED 97% COVERAGE

## FOR COMMERCIAL & GOVERNMENT INSURED PATIENTS<sup>1</sup>

REBYOTA is **covered** under medical policy utilizing the dedicated J-code (J1440) at numerous large, national & regional health plans.

Reimbursement is provided for claims that meet the criteria provided in payers policies.

Reimbursement rates are determined by HCP contract terms with the individual commercial payer.

**To confirm coverage for your patients, run a benefits verification today!**


### REBYOTA Connect offers benefits investigation support for providers

- ✓ Determine a patient's insurance coverage
- ✓ Verify whether a prior authorization (PA) is required
  - Medical benefit PA allows for a clinician to understand the payer criteria and adhere to it
- ✓ Assist with appeals process
- ✓ Provide guidance on potential billing codes and forms

#### Disclaimer

The coverage and reimbursement information provided by Ferring is intended to provide general information relevant to coding and reimbursement of Ferring products only. Coverage and payment policies for the same insurer, such as Medicare, can vary from one region to another and may change from time to time because of ongoing changes in government and insurance industry rules and regulations or the patient's specific benefit design. Please confirm HCPCS codes with the Pricing, Data Analysis and Coding (PDAC) contractor or your local DME MAC before processing claims. Ferring does not guarantee coverage or payment of its products.

The potential codes are provided for informational purposes only. Providers must use their independent judgment to select the codes that most appropriately describe the items or services provided to a patient. Providers are responsible for compliance with Medicare and other payer rules and requirements and for the information submitted with all claims and appeals. Providers should review applicable payer instructions and requirements and confirm the accuracy of their coding or billing practices with payers before claims or appeals are submitted.



For help in verifying a patient's insurance coverage...



Call **REBYOTA CONNECT**  
at 1-877-REBYOTA  
(1-877-732-9682)

or to begin enrollment, visit  
**REBYOTACONNECT.COM**

**REBYOTA<sup>®</sup>**  
(fecal microbiota, live-jslm)<sup>suspension,  
for rectal use</sup>

# REBYOTA<sup>®</sup> CONNECT – COMMITMENT PROGRAM

## FERRING STANDS BEHIND THE SERVICES WE OFFER

If you receive a positive coverage determination and reimbursement is subsequently denied, Ferring will reimburse the acquisition cost of the product.\*

\*Terms & Conditions apply. Offer not valid for REBYOTA administered at an Ambulatory Surgery/Surgical Center. Program valid until September 30, 2023.

## PROGRAM ELIGIBILITY

The REBYOTA Connect Commitment Program is available to providers who administered REBYOTA between May 1, 2023 and September 30, 2023 and meet the following criteria:

- Benefits Investigation is completed through REBYOTA Connect, with a positive determination of coverage
- Positive coverage determination must not have any requirement for prior authorizations, medical necessity, or other submission
- Claim is not reimbursed by the payer after subsequent appeals and investigation

## HOW TO UTILIZE THE REBYOTA CONNECT COMMITMENT:

- ✓ Benefits investigation submitted through REBYOTA Connect with a positive coverage determination
- ✓ HCP orders REBYOTA through the Ferring network of specialty distributors
- ✓ REBYOTA is administered to patient and office bills for reimbursement. If the claim for reimbursement is denied, office submits an appeal
- ✓ If appeal is denied, call REBYOTA Connect at 1-877-732-9682 to investigate claim denial and guide customer on appeals process
- ✓ Office submits a 2nd appeal. If 2nd appeal is denied, Ferring will reimburse the full product acquisition cost
- ✓ HCP certifies that patient has not been billed or patient will be reimbursed if a co-pay has already been collected

### References:

1. REBYOTA Connect Benefits Verifications for commercial AND government insured patients through June 15, 2023